Treatments for myocardial infarction have improved over the last few years but remain unsatisfactory for health care providers in three major respects, according to a new report from Datamonitor entitled World Cardiovascular Markets, available from Marketletter.
The three major areas are: - a necessity for rapid administration of the drugs with most beneficial effect; - available treatments, especially the most effective ones, are expensive; and - whilst treatments are effective, there is still room for improvement in reducing the mortality rate.
When asked what pharmaceutical companies should be doing to respond to weaknesses in thrombolytic therapies, specialists said that firms should be pursuing the development of safer and more effective thrombolytic agents.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze